NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CDXS

Codexis Inc

Jul 01 • 04:00PM ET

2.40

Dollar change -0.04
Percentage change -1.64	%

Healthcare • Biotechnology • USA • NASD

Peers: TSN DSM BIOX REGN INVA SGMO AVIR DVAX VNRX DTIL

| Held by: VTI IWM VXF IWO IBB VTWO FESM IWC ISMD IWN

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.99	Insider Own	3.23%	Shs Outstand	82.84M	Perf Week	-4.00%
Market Cap	198.83M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	141.93%	Shs Float	80.17M	Perf Month	4.35%
Enterprise Value	198.05M	PEG	-	EPS next Q	-0.19	Inst Own	83.15%	Short Float	7.93%	Perf Quarter	-10.78%
Income	-74.46M	P/S	3.99	EPS this Y	22.15%	Inst Trans	7.29%	Short Ratio	7.19	Perf Half Y	-51.71%
Sales	49.81M	P/B	4.01	EPS next Y	17.01%	ROA	-53.48%	Short Interest	6.36M	Perf YTD	-49.69%
Book/sh	0.60	P/C	3.30	EPS next 5Y	41.30%	ROE	-115.53%	52W High	6.08 -60.53%	Perf Year	-20.27%
Cash/sh	0.73	P/FCF	-	EPS past 3/5Y	-39.21% -33.31%	ROIC	-70.10%	52W Low	1.90 26.32%	Perf 3Y	-79.02%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-17.26% -2.82%	Gross Margin	62.03%	Volatility	6.07% 6.37%	Perf 5Y	-77.44%
Dividend TTM	-	EV/Sales	3.98	EPS Y/Y TTM	-5.03%	Oper. Margin	-134.40%	ATR (14)	0.16	Perf 10Y	-45.95%
Dividend Ex-Date	-	Quick Ratio	3.64	Sales Y/Y TTM	-32.89%	Profit Margin	-149.47%	RSI (14)	50.84	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	3.72	EPS Q/Q	-52.40%	SMA20	1.74%	Beta	2.52	Target Price	7.08
Payout	-	Debt/Eq	1.20	Sales Q/Q	-55.82%	SMA50	1.13%	Rel Volume	0.71	Prev Close	2.44
Employees	188	LT Debt/Eq	1.14	Earnings	May 14 AMC	SMA200	-29.72%	Avg Volume	884.49K	Price	2.40
IPO	Apr 22, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.44% -21.97%	Trades		Volume	628,840	Change	-1.64%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-24	Downgrade	The Benchmark Company	Buy → Hold
Jun-03-24	Resumed	Jefferies	Buy	$5
May-30-24	Initiated	Cantor Fitzgerald	Overweight	$11
Feb-29-24	Upgrade	The Benchmark Company	Hold → Buy
Nov-07-23	Downgrade	The Benchmark Company	Buy → Hold
Aug-07-23	Downgrade	TD Cowen	Outperform → Market Perform	$21 → $4
May-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Resumed	Piper Sandler	Overweight	$35
Mar-02-22	Resumed	Cowen	Outperform
Apr-12-21	Initiated	Piper Sandler	Overweight	$32
Mar-01-21	Initiated	Stifel	Buy	$30
Feb-26-21	Reiterated	H.C. Wainwright	Buy	$21 → $26
Mar-10-20	Initiated	The Benchmark Company	Buy
Jan-17-19	Upgrade	First Analysis Sec	Neutral → Outperform	$12 → $19
May-16-18	Initiated	Stephens	Overweight	$16
Oct-13-17	Reiterated	H.C. Wainwright	Buy	$8 → $8.50
May-31-17	Initiated	Jefferies	Buy	$8
Jan-26-17	Downgrade	First Analysis Sec	Overweight → Equal-Weight	$5.50
Jan-04-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-06-16	Initiated	H.C. Wainwright	Buy	$6

Show Previous Ratings

May-22-25 07:00AM	Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA (GlobeNewswire) +5.13%
May-21-25 04:05PM	Codexis to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 01:03PM	Q1 2025 Codexis Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with ... (GuruFocus.com)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:39PM	Loading…
04:39PM	Codexis: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-13-25 05:10PM	Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.32%
May-07-25 07:00AM	Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting (GlobeNewswire)
Apr-30-25 04:05PM	Codexis to Report First Quarter 2025 Financial Results on May 14 (GlobeNewswire)
Apr-24-25 10:01AM	Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-09-25 05:00PM	Codexis Announces Byron Dorgan to Retire from Board of Directors (GlobeNewswire) +17.26%
Apr-03-25 10:01AM	Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? (Zacks) -8.03%
07:00AM	Loading…
Apr-01-25 07:00AM	Codexis Appoints Cynthia Collins to Board of Directors (GlobeNewswire) -6.69%
Mar-24-25 07:00AM	Codexis Announces First Revenue-Generating Contract for ECO Synthesis Manufacturing Services (GlobeNewswire) +20.39%
Mar-07-25 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) -6.74%
Feb-28-25 11:02AM	Q4 2024 Codexis Inc Earnings Call (Thomson Reuters StreetEvents) -22.65%
02:36AM	Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Revenue Growth ... (GuruFocus.com)
Feb-27-25 06:35PM	Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -5.53%
05:36PM	Codexis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results (GlobeNewswire)
Feb-18-25 04:05PM	Codexis to Participate in TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-14-25 05:15PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) +5.12%
Feb-13-25 04:05PM	Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th (GlobeNewswire)
Feb-06-25 04:05PM	Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board (GlobeNewswire)
Jan-16-25 04:05PM	Codexis Appoints Christos Richards to Board of Directors (GlobeNewswire)
Jan-10-25 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) -7.77%
Dec-06-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) +15.22%
04:05PM	Loading…
Nov-19-24 04:05PM	Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +8.14%
Nov-14-24 04:05PM	Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics (GlobeNewswire) -7.43%
Nov-12-24 04:05PM	Codexis Announces Appointment of Raymond De Vre, PhD, to Board of Directors (GlobeNewswire)
04:05PM	Codexis Announces Appointment of Raymond De Vr , PhD, to Board of Directors (GlobeNewswire)
Nov-11-24 04:05PM	Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics (GlobeNewswire)
Nov-08-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Nov-04-24 04:05PM	Codexis to Participate in Upcoming Healthcare Conferences (GlobeNewswire) +9.46%
Nov-01-24 09:01AM	Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus ... (GuruFocus.com) +11.46%
Oct-31-24 05:30PM	Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:23PM	Codexis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-24-24 04:05PM	Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire) -7.27%
Oct-15-24 07:10AM	Codexis announces employment inducement grants (TipRanks) +5.28%
Oct-14-24 07:05AM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Oct-10-24 04:05PM	Codexis to Report Third Quarter 2024 Financial Results on October 31 (GlobeNewswire) +6.06%
Oct-09-24 05:56PM	Codexis Inc (CDXS) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
Oct-02-24 04:05PM	Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company (GlobeNewswire)
Oct-01-24 07:05AM	Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences (GlobeNewswire)
Sep-26-24 01:01PM	Casdin Capital, LLC Increases Stake in Codexis Inc (GuruFocus.com) +6.53%
Sep-24-24 01:03AM	Opaleye Management Inc. Expands Stake in Codexis Inc. (GuruFocus.com)
Sep-20-24 02:25AM	Opaleye Management Inc. Increases Stake in Codexis Inc. (GuruFocus.com)
Sep-06-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Sep-03-24 04:05PM	Codexis to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-20-24 04:05PM	Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting (GlobeNewswire)
Aug-16-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Aug-15-24 04:05PM	Codexis Publishes FY2023 Sustainability Disclosures (GlobeNewswire)
Aug-08-24 05:55PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -11.11%
04:51PM	Codexis: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-18-24 04:05PM	Codexis to Report Second Quarter 2024 Financial Results on August 8 (GlobeNewswire) +7.58%
Jul-10-24 01:30PM	Crosswalk Therapeutics Announces Acquisition of Rare Disease Assets from Codexis, Inc. (PR Newswire)
Jul-03-24 07:37AM	Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit (BioPharma Dive)
Jul-02-24 09:27AM	Crosswalk picks up Fabry, Pompe compounds from abandoned Takeda, Codexis collab (FierceBiotech.com)
Jul-01-24 04:05PM	Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets (GlobeNewswire)
Jun-12-24 05:48AM	Syntis Bio launches oral therapies for metabolic diseases (Pharmaceutical Technology)
May-22-24 04:25PM	Codexis to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -7.20%
May-20-24 04:05PM	Codexis to Participate in TD Cowen 2nd Annual Sustainability Week (GlobeNewswire) -5.82%
May-14-24 06:00AM	Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting (GlobeNewswire)
May-03-24 11:14AM	Codexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Call Transcript (Insider Monkey) +17.37%
06:47AM	Q1 2024 Codexis Inc Earnings Call (Thomson Reuters StreetEvents)
04:01AM	Codexis Inc (CDXS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-02-24 06:06PM	Codexis Inc (CDXS) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic Advances (GuruFocus.com) +7.40%
05:34PM	Codexis: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-18-24 04:05PM	Codexis to Report First Quarter 2024 Financial Results on May 2 (GlobeNewswire)
Apr-11-24 07:05AM	Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board (GlobeNewswire)
Feb-29-24 10:40AM	Codexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Call Transcript (Insider Monkey) +25.00%
07:08AM	Q4 2023 Codexis Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-24 06:50PM	Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates (Zacks) -10.36%
06:01PM	Codexis: Q4 Earnings Snapshot (Associated Press Finance)
04:59PM	Codexis Inc (CDXS) Reports Fiscal Year 2023 Financial Results (GuruFocus.com)
04:05PM	Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 04:05PM	Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche (GlobeNewswire) +5.61% +29.69%
08:05AM	Codexis to Participate in TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-20-24 08:05AM	Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board (GlobeNewswire) -9.12%
Feb-14-24 04:05PM	Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28 (GlobeNewswire) +14.89%
Feb-13-24 04:05PM	Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones (GlobeNewswire) -12.98%
Feb-01-24 04:05PM	seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting (GlobeNewswire)
Jan-08-24 07:03PM	Baillie Gifford Trims Position in Codexis Inc (GuruFocus.com) -5.92%
Dec-27-23 08:30AM	Codexis Announces Purchase Agreement with Nestl Health Science for CDX-7108 (GlobeNewswire)
Dec-14-23 06:45AM	Aldevron signs agreement to acquire license to Codex HiCap RNA Polymerase (Pharmaceutical Business Review) +41.15%
Dec-13-23 04:06PM	Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex HiCap RNA Polymerase (GlobeNewswire)
04:05PM	Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis Platform (GlobeNewswire)
Dec-11-23 07:05AM	Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing (GlobeNewswire) -8.33%
Nov-29-23 02:46PM	3 Synthetic Biology Stocks Likely to Mint New Millionaires (InvestorPlace) +7.05%
Nov-28-23 04:05PM	Codexis to Host Virtual KOL Event on its ECO Synthesis Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023 (GlobeNewswire) +5.09%
Nov-14-23 04:05PM	Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +18.07% +6.63%
Nov-03-23 09:14AM	Q3 2023 Codexis Inc Earnings Call (Thomson Reuters StreetEvents) +7.22%
08:58AM	Codexis, Inc. (NASDAQ:CDXS) Q3 2023 Earnings Call Transcript (Insider Monkey)

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Jun 27 '25	Buy	2.39	100,000	239,000	12,350,000	Jul 01 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 12 '25	Buy	2.25	100,000	225,000	12,100,000	Jun 16 04:59 PM
Opaleye Management Inc.	10% Owner	Jun 13 '25	Buy	2.23	99,102	220,997	12,199,102	Jun 16 04:59 PM
Opaleye Management Inc.	10% Owner	Jun 16 '25	Buy	2.24	50,898	114,012	12,250,000	Jun 16 04:59 PM
Opaleye Management Inc.	10% Owner	May 23 '25	Buy	2.36	2,320,000	5,475,200	11,995,000	May 28 04:05 PM
Opaleye Management Inc.	10% Owner	May 28 '25	Buy	2.36	5,000	11,800	12,000,000	May 28 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 30 '25	Buy	2.31	25,000	57,660	9,655,000	May 02 04:05 PM
Opaleye Management Inc.	10% Owner	May 01 '25	Buy	2.32	20,000	46,436	9,675,000	May 02 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 25 '25	Buy	2.24	25,000	55,915	9,630,000	Apr 29 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 16 '25	Buy	2.13	70,000	148,890	9,560,000	Apr 17 06:07 PM
Opaleye Management Inc.	10% Owner	Apr 17 '25	Buy	2.09	45,000	94,162	9,605,000	Apr 17 06:07 PM
Opaleye Management Inc.	10% Owner	Apr 15 '25	Buy	2.23	25,000	55,720	9,490,000	Apr 17 06:07 PM
Opaleye Management Inc.	10% Owner	Apr 08 '25	Buy	1.98	100,000	198,380	9,465,000	Apr 09 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 03 '25	Buy	2.30	75,000	172,740	9,365,000	Apr 03 07:39 PM
Opaleye Management Inc.	10% Owner	Apr 01 '25	Buy	2.48	35,000	86,772	9,285,000	Apr 03 07:39 PM
Opaleye Management Inc.	10% Owner	Apr 02 '25	Buy	2.46	5,000	12,276	9,290,000	Apr 03 07:39 PM
Opaleye Management Inc.	10% Owner	Mar 21 '25	Buy	2.54	92,923	236,266	9,250,000	Mar 24 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 20 '25	Buy	2.54	7	18	9,157,077	Mar 24 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 13 '25	Buy	2.54	85,000	216,155	9,150,000	Mar 14 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 06 '25	Buy	2.61	100,000	261,350	9,065,000	Mar 10 05:16 PM
Opaleye Management Inc.	10% Owner	Mar 04 '25	Buy	2.64	55,000	145,398	8,955,000	Mar 06 04:51 PM
Opaleye Management Inc.	10% Owner	Mar 05 '25	Buy	2.69	10,000	26,875	8,965,000	Mar 06 04:51 PM
Opaleye Management Inc.	10% Owner	Feb 28 '25	Buy	2.99	147,649	441,175	8,852,649	Mar 04 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 03 '25	Buy	2.81	47,351	133,165	8,900,000	Mar 04 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 10 '25	Buy	4.18	22,500	94,149	8,677,500	Feb 12 07:42 PM
Opaleye Management Inc.	10% Owner	Feb 12 '25	Buy	4.00	15,000	59,932	8,705,000	Feb 12 07:42 PM
Opaleye Management Inc.	10% Owner	Feb 11 '25	Buy	4.11	12,500	51,400	8,690,000	Feb 12 07:42 PM
Opaleye Management Inc.	10% Owner	Jan 31 '25	Buy	4.29	45,000	193,185	8,655,000	Jan 31 07:08 PM
Opaleye Management Inc.	10% Owner	Jan 30 '25	Buy	4.49	20,000	89,782	8,610,000	Jan 31 07:08 PM
Opaleye Management Inc.	10% Owner	Dec 30 '24	Buy	4.70	35,000	164,392	8,580,000	Jan 02 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 31 '24	Buy	4.66	10,000	46,603	8,590,000	Jan 02 04:05 PM
Opaleye Management Inc.	10% Owner	Oct 25 '24	Buy	2.91	25,000	72,720	8,545,000	Oct 28 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 24 '24	Buy	2.94	80,000	234,856	8,515,000	Sep 26 03:21 PM
Opaleye Management Inc.	10% Owner	Sep 25 '24	Buy	2.86	5,000	14,290	8,520,000	Sep 26 03:21 PM
Opaleye Management Inc.	10% Owner	Sep 20 '24	Buy	3.01	1,055,000	3,175,550	8,390,000	Sep 23 05:19 PM
Opaleye Management Inc.	10% Owner	Sep 23 '24	Buy	2.94	45,000	132,484	8,435,000	Sep 23 05:19 PM
Opaleye Management Inc.	10% Owner	Sep 18 '24	Buy	3.16	61,000	192,992	7,380,000	Sep 19 06:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CDXS

Codexis Inc

Upgrade your FINVIZ experience